Clinical Effect of Carbamazepine in the Treatment of Newly Diagnosed Partial Epilepsy and its Influence on Cognitive Function
Objective To explore the clinical effect of carbamazepine(CBZ)treatment and its influence on cognitive function in patients with newly diagnosed partial epilepsy.Methods A total of 136 patients with newly diagnosed partial epilepsy who were treated in our hospital from March 2020 to September 2022 were selected.They were randomly divided into the study group(n=68)and the control group(n=68).The control group was treated with topiramate tablets,and the research group was treated with CBZ combined with topiramate tablets.The clinical efficacy,cognitive function,quality of life,serum indicators,and adverse reactions of the two groups were compared.Results In the total effective rate of treatment,in comparision of the control group(80.88%),the study group(95.59%)was higher(P＜0.05).After 3 months of treatment,the scores of MoCA in both groups were increased(P＜0.05),and in comparision of the control group,the scores in the study group were higher(P＜0.05).After treatment,the scores of QOLIE-31 in both groups were improved(P＜0.05),and in comparision of the control group,the study group was higher(P＜0.05).After treatment,the levels of NPY and GFAP in both groups were decreased(P＜0.05),and in comparision of the control group,the levels in the study group were lower(P＜0.05).In the incidence of adverse reactions,in comparision of the control group(20.59%),the study group(4.41%)was lower(P＜0.05).Conclusion CBZ treatment for newly diagnosed partial epilepsy can improve clinical efficacy,enhance cognitive function,improve quality of life,improve serum indicators and reduce adverse reactions.
carbamazepinenewly diagnosed partial epilepsyclinical efficacycognitive function
国家科技期刊平台
NSTL
万方数据
维普
